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In addition to their stem/progenitor properties, mesenchymal stromal cells (MSCs) possess broad immuno-
regulatory properties that are being investigated for potential clinical application in treating immune-based
disorders. An informed view of the scope of this clinical potential will require a clear understanding of the
dynamic interplay between MSCs and the innate and adaptive immune systems. In this Review, we outline
current insights into the ways in which MSCs sense and control inflammation, highlighting the central role
of macrophage polarization. We also draw attention to functional differences seen between vivo and in vitro
contexts and between species. Finally, we discuss progress toward clinical application of MSCs, focusing on
GvHD as a case study.Introduction
Mesenchymal stromal cells (MSCs) are adult, fibroblast-like mul-
tipotent cells characterized by the ability to differentiate into tis-
sues of mesodermal origin, such as adipocytes, chondroblasts,
and osteoblasts (Friedenstein et al., 1974; Pittenger et al., 1999).
First identified and isolated from the bone marrow (BM), MSCs
can now be expanded from a variety of other tissues including
adipose tissue (AT), umbilical cord blood (UCB), skin, tendon,
muscle, and dental pulp (Im et al., 2005; Campagnoli et al.,
2001; Kawashima, 2012). MSCs can be isolated based on their
ability to adhere to plastic culture dishes, and they are capable
of significant expansion by consecutive in vitro passaging (Pit-
tenger et al., 1999).
Historically, a challenge that has faced the field has been the
lack of uniform criteria to define MSCs, which has hindered
efforts to compare results obtained from different experimental
and clinical studies. In response to this challenge, the Interna-
tional Society for Cellular Therapy formulated minimal criteria
for defining MSCs in order to create a broader consensus for
more uniform characterization of these cells (Dominici et al.,
2006). Although there remains much debate over how to define
such a broad population of cells, it is clear that some populations
of MSCs are capable of exhibiting stem cell function in vivo
(Keating, 2012; Sacchetti et al., 2007).
In addition to their stem/progenitor properties,MSCshave also
been shown topossessbroad immunoregulatory abilities andare
capable of influencing both adaptive and innate immune re-
sponses. Recent findings have demonstrated thatMSCs actively
interact with components of the innate immune system and that,
through these interactions, they display both anti-inflammatory
and proinflammatory effects (Keating, 2012; Le Blanc and Mou-
giakakos, 2012; Prockop and Oh, 2012). This ability of MSCs to
adopt a different phenotype in response to sensing an inflamma-
tory environment is not captured in assays that are commonly
used to characterize these cells, but it is crucial for understanding
their therapeutic potential in immune-mediated disorders. Much
of the characterization of these properties has been conducted
in vitro, and there are outstanding questions about the degree392 Cell Stem Cell 13, October 3, 2013 ª2013 Elsevier Inc.to which they represent activities that are functionally relevant
for endogenous and/or transplanted cells in vivo. The putative
role of stromal cells in maintaining tissue homeostasis serves
as the basis for their application in disorders resulting from auto-
geneic or allogeneic immune responses, including Graft-versus-
Host Disease (GvHD) and autoimmune disorders (Le Blanc et al.,
2008; Duijvestein et al., 2010) and can be referred to as ‘‘stromal
cell therapy.’’ The application ofMSCs in these inflammatory dis-
ease settings suggests that the stem cell properties of MSCs,
including their ability to engraft, may be independent from their
ability to regulate tissue homeostasis.
Animal models are of critical importance for translating in vitro
immune regulatory properties of MSCs into therapeutic applica-
tion anddissectingmechanismsof efficacy. Althoughmurine and
human MSCs share properties such as multilineage differentia-
tion capacity, they are also distinct with respect to other proper-
ties. A notable example of this divergence is the susceptibility of
murine BM-derived MSCs to transform upon culture expansion.
In addition, murine and human MSCs employ different effector
molecules (i.e., nitric oxide [NO] and indolamine 2,3 dioxygenase
[IDO], respectively) for immune regulation, for example during
suppression of T cell proliferation (Ren et al., 2008; Franc¸ois
et al., 2012). In some studies, human MSCs have been applied
in mouse models of either immune competent or immune defi-
cient mice. These differences should be taken into consideration
when interpreting in vivo effects of murine MSCs, especially in
light of efforts to look at clinical application of MSCs.
In this Review we discuss the regulatory properties of MSCs
with respect to their ability to modify tissue homeostasis and
inflammation. MSCs are sensors of inflammation and are able
to adopt a proinflammatory or anti-inflammatory phenotype by
interfering with innate and adaptive immune responses
both in vitro and in vivo. For the sake of clarity, these integrated
responses are discussed separately. In addition, a compar-
ison between murine and human MSCs will be also be covered.
Finally, the clinical application of MSCs in the setting of
acute GvHD treatment and biomarker development will be
reviewed.
A B Figure 1. Polarization of MSCs into a
Proinflammatory and Anti-Inflammatory
Phenotype
(A) In the presence of an inflammatory environ-
ment (high levels of TNF-a and IFN-g), MSCs
become activated and adopt an immune-sup-
pressive phenotype (MSC2) by secreting high
levels of soluble factors, including IDO, PGE2,
NO, TGF-b, Hepatocyte Growth Factor (HGF),
and hemoxygenase (HO), that suppress T cell
proliferation. The switch toward MSC1 or MSC2
type may also depend on MSC stimulation
through Toll-like receptors (TLRs) expressed
on their surface (Waterman et al., 2010). Trig-
gering through double stranded RNA (dsRNA)
derived from viruses stimulates TLR3 on the
surface of MSCs and may induce the polariza-
tion into the MSC2 anti-inflammatory type.
Together with constitutive secretion of TGF-b by
MSCs, emergence of regulatory T cells (Tregs) is
favored.
(B) In the absence of an inflammatory environ-
ment (low levels of TNF-a and IFN-g), MSCs
may adopt a proinflammatory phenotype (MSC1)
and enhance T cell responses by secreting
chemokines that recruit lymphocytes to sites
of inflammation (e.g, MIP-1a and MIP-1b,
RANTES, CXCL9, and CXCL10) (Ren et al., 2008;
Li et al., 2012). These chemokines bind to
receptors present on T cells, i.e., CCR5 and
CXCR3. Polarization to a proinflammatory MSC1
phenotype can also be influenced by activation
of TLR4 by low levels of lipopolysaccharide
(LPS) derived from Gram-negative bacteria.
The levels of immune-suppressive mediators,
such as IDO and NO, are low when the MSC1 phenotype is adopted. The balance between these opposing pathways may serve to promote host
defense on one hand and at the same time create a loop that prevents excessive tissue damage and promotes repair.
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Microenvironment: Impact of Innate Immunity
Inflammation serves as a localized or systemic protective
response elicited by infection, injury, or tissue destruction and
serves to eliminate pathogens and preserve host integrity. Within
hours after the onset of an inflammatory response,molecules ex-
pressed by pathogens or associated with tissue injury are recog-
nized by Toll-like receptors (TLRs) present on innate effector
cells. TLR ligation triggers phagocytosis and the release of in-
flammatory mediators, which may initiate innate immune re-
sponses that provide a first line of nonspecific defense, mainly
through the activation of phagocytic cells, including macro-
phages and neutrophils (Gordon andMantovani, 2011). TLR liga-
tionmay not only activate phagocytic cells but also stromal cells,
including MSCs, thus creating an inflammatory environment
(Mantovani et al., 2013; Waterman et al., 2010).
MSCs Induce Macrophage Polarization in an
Inflammatory Environment: Contribution of In Vitro
Studies
Much of what is known about immunmodulatory properties of
MSCs has been discovered through cocultures of MSCs and
immune cells. Human and mouse MSCs dynamically express a
number of distinct and overlapping TLRs in culture, and in vitro
stimulation of specific TLRs affects the subsequent immune
modulating responses of MSCs (Nemeth et al., 2010; Tomchuck
et al., 2008; Delarosa et al., 2012). Under hypoxic culture condi-
tions, stimulation of MSCs with the proinflammatory cytokines
IFN-g, TNF, IFN-a, and IL-1b upregulates expression of a subset
of TLRs, thus increasing the sensitivity of MSCs to the inflamma-tory milieu (Raicevic et al., 2010). However, prolonged stimula-
tion with TLR ligands causes downregulation of TLR2 and
TLR4 (Mo et al., 2008), most likely as a self-regulatory mecha-
nism to prevent overactive skewing of the immune response.
To direct appropriate immune responses to a diversity of path-
ogenic insults, the different TLRs are activated by specific
endogenous or pathogen-associated molecules, including lipo-
polysaccharide (LPS) from Gram-negative bacteria (TLR4) and
double strand RNA (dsRNA) carried by some viruses (TLR3).
Waterman et al. (2010) have suggested that MSCs may polarize
into two distinctly acting phenotypes following specific TLR
stimulation, resulting in different immune modulatory effects
and distinct secretomes. The TLR4-primed MSC population ex-
hibits a proinflammatory profile (MSC1) and the TLR3-primed
MSC population delivers anti-inflammatory signals (MSC2)
(Figure 1). Although the molecular pathways that promote a
proinflammatory or anti-inflammatory secretome following TLR
ligation remain unclear, the concept of MSC polarization into
proinflammatory and anti-inflammatory cells provides an attrac-
tive model to explain and interrogate the apparently contradic-
tory roles of MSCs in inflammation.
Within the innate immune system, it is well established that
macrophages are key players in initiating and controlling inflam-
mation (Mantovani et al., 2013), and MSCs can influence macro-
phage function depending on the inflammatory context (see
sections below). Monocytes arriving at an inflammatory environ-
ment can develop into activated M1 macrophages or convert
into alternatively activated M2 macrophages depending on
microenvironmental cues. While M1 macrophages stimulateCell Stem Cell 13, October 3, 2013 ª2013 Elsevier Inc. 393
A B Figure 2. Interactions between MSCs and
Monocytes: MSCs Balance the Polarization
of Monocytes (M0) toward M1 and M2
Macrophages
(A) MSCs constitutively produce IL-6, which po-
larizes monocytes (M0) toward anti-inflammatory
IL-10-producing M2 macrophages (Eggenhofer
and Hoogduijn, 2012). This polarization is initiated
by and dependent on a combination of cell-cell
contact mechanisms and the secretion of soluble
factors, including IDO and PGE2. The polarizing
effect of MSCs on M2 macrophages is closely
linked to their ability to favor the emergence of
CD4+CD25+FoxP3+ regulatory T cells (Tregs). The
emergence of Tregs can be supported by MSCs by
indirect and direct mechanisms: indirectly via the
production of CCL18 by MSC-induced M2 mac-
rophages and directly via the production of TGF-b
by MSCs (Melief et al., 2013a). Other molecules
involved in the MSC-mediated generation of Tregs
are Prostaglandin E2 (PGE2) and soluble HLA-G
(sHLA-G).
(B) In the absence of IL-6, MSCs induce the po-
larization of M0 toward proinflammatory M1 mac-
rophages through secretion of IFN-g and IL-1 and
surface expression of CD40L. M1 macrophages
secrete IFN-g and TNF-a and express cos-
timulatory molecules on their surface that promote
T cell activation. High levels of proinflammatory
signals, including TNF-a and IFN-g produced by
activated T cells or proinflammatory M1 macrophages, act as a feedback mechanism and induce the anti-inflammatory pathway shown in (A). The
balance between anti- and proinflammatory pathways is crucial in controlling host defense and inflammation and preventing excessive tissue damage.
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macrophages secrete a combination of cytokines (including
high levels of IL-10 and TGF-b1 and low levels of IL-1, IL-6,
TNF-a, and IFN-g) that together exert an anti-inflammatory effect
and allow tissue regeneration following inflammation (Mantovani
et al., 2013).
MSCs actively interact with components of the innate immune
system and influence their subsequent immunoregulatory and
regenerative behavior (Keating, 2012; Le Blanc and Mougiaka-
kos, 2012). The production of proinflammatory cytokines by
M1 macrophages or activated T cells may activate MSCs and
trigger the release of mediators that skew the differentiation of
monocytes toward an anti-inflammatory profile and ultimately
toward M2 macrophages (Le Blanc and Mougiakakos, 2012)
(Figure 2). In addition to polarization of MSCs, macrophage po-
larization provides a supplementary mechanism to maintain bal-
ance between proinflammatory and anti-inflammatory effects.
This dynamic regulatory feedback between MSCs and macro-
phages generates a profound sensitivity to the surrounding
microenvironment that is displayed through the ability to switch
between proinflammatory and anti-inflammatory activities. In
both cases, switching mechanisms rely on the production of sol-
uble mediators, including the immunosuppressive factors induc-
ible NO synthase (iNOS, for mice) and IDO (for humans), which
are induced by proinflammatory cytokines. The concentrations
of these factors may be critical in triggering the switch between
proinflammatory and anti-inflammatory MSCs and, thereby, also
between M1 and M2 macrophages (Ren et al., 2008).
MSCs Enhance Immune Responses during Early-Stage
Inflammation
The proinflammatory activities of MSCs may be beneficial in the
early phase of inflammation and help in mounting a proper
immune response. During the acute phase of inflammation, neu-394 Cell Stem Cell 13, October 3, 2013 ª2013 Elsevier Inc.trophils migrate toward the site of inflammation where they accu-
mulate within minutes and act mainly through phagocytosis
(Kolaczkowska and Kubes, 2013). In mice, the recognition of mi-
crobial molecules by tissue-resident MSCs results in increased
production of growth factors, such as IL-6, IL-8, granulocyte-
macrophage colony-stimulating factor (GM-CSF), and macro-
phage migration inhibitory factor (MIF), that recruit neutrophils
and enhance their proinflammatory activity (Brandau et al.,
2010). Moreover, TLR3-activated human BM-MSCs (MSC2)
promote the in vitro survival of resting and activated neutrophils
in an IL-6-, IFN-b-, and GM-CSF-dependent manner (Cassatella
et al., 2011).
In addition to neutrophils, immune responses may be
enhanced by MSCs through the production of chemokines that
recruit lymphocytes to sites of inflammation. Human MSCs pro-
duce the chemokines CXCL-9, CXCL-10, and CXCL-11 upon
stimulation with proinflammatory cytokines. In vitro studies with
murine and human MSCs suggest that these stimulatory effects
only occurwhenMSCs are exposed to insufficient levels of proin-
flammatory cytokines, such as TNF-a and IFN-g. Under these
immune-enhancing conditions, murine MSCs elicit insufficient
levels of NO to inhibit T cell proliferation. Indeed, inhibition of
iNOS or its genetic ablation resulted in strong enhancement of
T cell proliferation by murine MSCs (Ren et al., 2008; Li et al.,
2012; Shi et al., 2012). Under similar conditions, human MSCs
produce insufficient IDO (rather than iNOS) to suppressTcell pro-
liferation (Figure 1). These data suggest that iNOS formurine cells
or IDO for human cells may serve as a molecular switch between
immune-suppressive to immune-enhancing effects of MSCs.
MSCs Suppress Immune Responses and Inflammation
to Promote Tissue Homeostasis
When exposed to sufficient levels of proinflammatory cytokines,
MSCs may respond by adopting an immune-suppressive MSC
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stasis through polarization toward anti-inflammatory cells and
M2 macrophages in vitro. Coculture of monocytes with human
or mouse BM-MSCs promotes the formation of M2 macro-
phages (Eggenhofer and Hoogduijn, 2012) (Figure 2) and this is
dependent on both cellular contact and soluble factors,
including prostaglandin E2 (PGE2) and catabolites of IDO activity
such as kynurenine (Ne´meth et al., 2009; Eggenhofer and Hoog-
duijn, 2012). Moreover, activation of MSCs with IFN-g, TNF-a,
and LPS increases the expression of cyclooxygenase 2 (COX2)
and IDO in BM-MSCs, thereby further promoting a homeostatic
response toward M2 macrophage polarization (Ne´meth et al.,
2009; Franc¸ois et al., 2012). Through the release of chemokine
(C-C motif) ligands CCL2, CCL3, and CCL12, human and mouse
BM-MSCs can recruit monocytes and macrophages into in-
flamed tissues and promote wound repair (Chen et al., 2008).
This polarizing effect of MSCs on M2 macrophages is closely
linked with the ability of MSCs to favor the emergence of reg-
ulatory T cells (Tregs), which are involved in immunosuppres-
sion. TGF-b is a factor that is constitutively produced by
MSCs and that directly induces Tregs in a monocyte-depen-
dent manner. M2 polarized macrophages also produce IL-10,
which is directly immune suppressive. In addition, M2 macro-
phages produce CCL18, a factor that in conjunction with
TGF-b promotes the generation of Tregs (Melief et al., 2013a)
(Figure 2). The MSC-derived factors that induce the differentia-
tion of monocytes toward M2 macrophages have not been
identified.
These data underline the importance of the interactions
between MSCs and the innate immune system in balancing
proinflammatory and anti-inflammatory responses in order to
preserve tissue integrity. The central role of macrophages in
the induction of the anti-inflammatory effect of MSCs is depicted
in Figure 2.
Role of MSCs in Orchestrating Adaptive Immune
Responses
The adaptive immune system is antigen-specific and allows the
development of immunological memory. It comprises CD4+
T-helper and CD8+ cytotoxic T lymphocytes that deliver a
tailored antigen-specific immune response following antigen
processing and presentation by antigen-presenting cells
(APCs). T helper cells comprise a subpopulation of cells, Tregs,
which are specialized in suppression of T cell-mediated immune
responses. The innate immune system plays a crucial part in the
initiation and subsequent direction of adaptive immune re-
sponses, as well as in the removal of pathogens that have
been targeted by an adaptive immune response (Yamane and
Paul, 2013; Gratz et al., 2013).
MSC and Effector T Cell Immunity
As with innate immunity, much of what is known about the inter-
action of MSCs with the adaptive immune system is through
in vitro studies. MSCs are able to suppress in vitro T-lymphocyte
proliferation induced by cellular or nonspecific mitogenic stimuli
(Di Nicola et al., 2002) through the secretion of soluble factors
that include TGF-b, Hepatocyte Growth Factor (HGF), PGE2,
IDO, NO, and hemoxygenase (HO) (Stagg and Galipeau 2013).
The release of these suppressive factors is enhanced following
stimulation of MSCs with TNF-a and IFN-g, although unstimu-lated MSCs also produce these mediators. In human cells IDO
promotes the degradation of tryptophan into kynurenine and
other catabolites that have been shown to not only suppress
T cell proliferation, but also induce Treg differentiation. The sup-
pression of T cell proliferation involves both CD4+ and CD8+
T cells; IFN-g production and cytotoxicity are also inhibited in a
dose-dependent manner (Krampera et al., 2003; Aggarwal and
Pittenger, 2005). In murine cells, the critical role of NO in sup-
pressing T cell proliferation is also supported by the observation
that in vitro proliferation of murine T cells is boosted by the
addition of the NO inhibitor L-NMMA (Li et al., 2012). Similarly,
addition of iNOS/ MSCs induces a dramatic increase in
T cell proliferation in coculture assays. While MSCs directly pro-
duce soluble factors that suppress T cell proliferation, it has also
been suggested that the ability of MSCs to suppress T cell pro-
liferation in vitro is monocyte dependent, since MSCs show a
reduced inhibitory action on T cells in the absence of monocytes
(Cutler et al., 2010; Franc¸ois et al., 2012).
MSCs and Regulatory T Cells
Several studies have documented the ability of MSCs to polarize
T cells toward a regulatory phenotype (Burr et al., 2013) that
serves as an important mechanism by which MSCs dampen
inflammation. Tregs comprise a subpopulation of T helper cells,
are specialized in suppression of T cell-mediated immune re-
sponses, and characteristically express the forkhead box P3
(FoxP3) transcription factor. There are twomain subsets of Tregs
including a population of FoxP3+ natural Tregs, which are
thymus derived and specific for self antigens and induced or
adaptive Tregs that are derived frommature CD4+CD25Foxp3
precursors in the periphery following inflammatory stimuli
(Chaudhry and Rudensky, 2013).
In vitro coincubation of human MSCs with peripheral blood
mononuclear cells (PBMCs) induced the differentiation of CD4+
T cells into CD25+FoxP3+-expressing regulatory T cells (induced
Tregs), a process involving direct MSC contact with helper
T cells and PGE2 and TGF-b secretion (Maccario et al., 2005;
English et al., 2009). The generation of Tregs was reported to
be monocyte dependent and was not observed in cocultures
of MSCs and purified CD4+ T cells or monocyte-depleted
PBMCs, but it could be restored by the addition of monocytes
(Melief et al., 2013a).
Following addition of mitogen-stimulated T cells, MSC-
induced Tregs potently suppressed the T cell proliferative
response (English et al., 2009). Secretion of HLA-G5 by MSCs
has also been shown to promote MSC-induced Treg genera-
tion. Blocking experiments using neutralizing anti-HLA-G
antibody demonstrated that HLA-G5 contributes first to the
suppression of allogeneic T cell proliferation and then to the
expansion of CD4+CD25+FoxP3+ Tregs (Selmani et al., 2008).
In this process, both the activation state of CD4+ T cells and
the cytokine milieu may play a role. By exerting inhibitory effects
on APCs that process antigens and present them to T cells,
MSCs can generate regulatory APCs characterized by their
Treg-promoting activity.
All together, these studies indicate that MSCs are able to
recalibrate the balance between inflammatory effector T cells
and anti-inflammatory Tregs. This process is tightly related
to polarization of monocytes toward anti-inflammatory (M2)
macrophages (Figure 2). By linking cytokine-mediated immuneCell Stem Cell 13, October 3, 2013 ª2013 Elsevier Inc. 395
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Treg cells, an amplification of the anti-inflammatory response
is obtained.
In Vivo Regulation of Inflammation by MSCs
Ex-Vivo-Expanded MSCs Influence Macrophage
Polarization and Immune Responses In Vivo
While the concept of macrophage polarization may explain the
apparent discrepancy between proinflammatory and anti-in-
flammatory activities of MSCs, the biological relevance of these
findings remains unclear. In several recent studies, the ability of
MSCs to polarize macrophages has also been investigated
in vivo. In a sepsis model, the administration of mouse BM-
MSCs decreased lethality; however, this effect was not observed
after macrophage depletion or after administration of IL-10-
specific neutralizing antibodies, suggesting that MSC-induced
macrophage polarization also occurs in vivo and may result in
reduced tissue damage (Ne´meth et al., 2009). It has been
recently observed that Nes+ MSCs respond to TLR4 ligation by
upregulating monocyte chemotactic protein-1 (MCP1) expres-
sion, which induces CCR2-dependent migration of monocytes
from the BM into the circulation, which may serve as a mecha-
nism to further promote this process (Shi et al., 2011).
In the same model, MSCs improved survival of mice by
enhancing the ability of neutrophils to phagocytize bacteria
and promote bacterial clearance (Hall et al., 2013; Ne´meth
et al., 2009). It was also shown that MSCs, through the induc-
tion of IL-10 by monocytes and macrophages, can prevent
neutrophils from migrating into tissues, thereby preventing
oxidative damage. The inhibition of neutrophil migration into tis-
sues is associated with a higher neutrophil count in the blood,
allowing more efficient bacterial clearance and, at the same
time, preventing excessive tissue damage. These data suggest
that during the early phase of inflammation, MSCs may play a
role in promoting neutrophil migration and activation in order
to enhance innate immune responses, but during later
stages, they may switch toward an inhibitory phenotype result-
ing in inhibition of migration to protect tissues against oxidative
injury.
Similar observations were made in a model of endotoxin-
induced lung injury, in which intrapulmonary delivery of mouse
BM-MSCs decreased the production of TNF-a and chemokine
ligand CXCL2 and increased the production of IL-10 by alveolar
macrophages (Gupta et al., 2007). On the same line, in a
zymosan-induced peritonitis model, infusion of human BM-
MSCs resulted in secretion of TNF-stimulated gene 6 (TSG6), a
molecule that interferes with TLR2 nuclear factor-kB (NF-kB)
signaling in peritoneal macrophages, thereby attenuating their
activation (Choi et al., 2011). In this model the therapeutic effects
of MSCs seem to be mediated by endocrine rather than para-
crine mechanisms, suggesting that homing to a site of injury is
not necessarily required for therapeutic efficacy.
The role of macrophages in MSC-induced Treg formation has
been recently confirmed in mouse models of fibrillin-mutated
systemic sclerosis and experimental colitis. Infusion of murine
BM-MSCs induced transient T cell apoptosis, which triggered
macrophages to produce high levels of TGF-b, eventually
enhancingCD4+CD25+FoxP3+Treg generation. This effect trans-
lated into amelioration of the disease phenotype (Akiyama et al.,396 Cell Stem Cell 13, October 3, 2013 ª2013 Elsevier Inc.2012). The polarization of T cells toward a Treg phenotype has
been also shown in other experimental models of autoimmune
and inflammatory diseases, such as SLE, diabetes, and colitis
(Choi et al., 2012; Madec et al., 2009; Duijvestein et al., 2011).
Injection of iNOS/MSCs into the footpad of mice generated
an aggravated response to ovalbumin-induced Delayed Type
Hypersensitivity (DTH) as measured by an increase in footpad
thickness and enhanced leukocyte infiltration. Conversely,
administration of unmodified MSCs reduced footpad thickness
and leukocyte infiltration. These results confirm the dual regula-
tory role of NO in enhancing or suppressing T cell immunity (Ren
et al., 2008; Li et al., 2012).
Insufficient homing of systemically delivered MSCs is consid-
ered a major limitation of MSC-based therapies, caused in part
by inadequate expression of cell surface adhesion receptors.
The modification of human MSC surface with a construct con-
taining sialyl Lewis(x) that is found on the surface of leukocytes
and mediates cell rolling within inflamed tissue has been shown
to allow rolling of MSCs on inflamed endothelium in vivo in mice
and homing to inflamed tissue with higher efficiency compared
with native MSCs (Sarkar et al., 2010). This model has been
taken one step further by the overexpression of IL-10 in engi-
neered MSCs. The systemic administration of these cells in an
ear-inflammation model resulted in a superior anti-inflammatory
effect in vivo that was dependent on rapid migration to the
inflamed ear. In spite of the rapid clearance ofMSCs from the cir-
culation following systemic injection (Lee et al., 2009), these re-
sults show that MSCs can be successfully used for the targeted
delivery of immune-suppressive molecules to distant sites of
inflammation (Levy et al., 2013).
Taken together, these in vivo results indicate that MSCs
actively interact with cells of the innate immune system and
modulate their function to establish a fine balance between path-
ogen elimination and repair processes, aiming at controlling
inflammation, preventing organ failure, and preserving tissue
homeostasis. The further elucidation of mechanisms that trigger
a functional switch betweenMSCphenotypes remains an impor-
tant research goal for future studies.
MSCsAreResponsive to theHostMicroenvironment and
Participate in Immune Surveillance
Several reports have indicated that MSCs are not constitutively
inhibitory but need to be activated by an inflammatory environ-
ment in the host in order to have their immunoregulatory effect
mediated (Krampera, 2011). This notionwas based on the obser-
vation that anti-IFN-g receptor antibodies can block the sup-
pressive effect of MSCs. The simultaneous presence of other
inflammatory cytokines can influence the immunosuppressive
effect of MSCs as well as induce changes in their immunopheno-
type. IFN-g, TNF-a, and IL-1b are able to induce the upregulation
of HLA-class I, ICAM-1, and VCAM-1 on the surface of MSCs,
while IFN-g alone can induce the activity of IDO (Ren et al.,
2008). Inflammatory stimuli induce MSCs to secrete molecules
involved in the regulation of tissue homeostasis, including NO,
IDO, PGE2, HO-1, TSG6, CCL2 chemokine, IL-10, and galectins
(Shi et al., 2012).
According to the activation model, MSCs are most effective
when administered after the onset of an inflammatory response.
In amouseGvHDmodel, MSC administration on the same day of
bone marrow transplantation (BMT) had no protective effect
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after BMT significantly suppressed the progression of GvHD
and abrogated the related symptoms (Polchert et al., 2008). It
has been proposed that pretreatment of MSCs with inflamma-
tory cytokines may mimic the inflammatory environment and
may enhance their potential therapeutic efficacy. In support of
this theory, administration of IFN-g-pretreated MSCs protected
mice from GvHD-induced death (Polchert et al., 2008). Other
studies have indicated that pretreatment with inflammatory cyto-
kines can amplify the therapeutic effect of MSCs in animal
models of colitis and acute myocardial ischemia/reperfusion
injury (Duijvestein et al., 2011; Luo et al., 2012). These data indi-
cate the importance of the local inflammatory conditions in regu-
lating the anti-inflammatory effects of MSCs. Further dissection
of the molecular mechanisms involved in these interactions will
be crucial for the development of novel MSC-based therapies.
There is ample evidence that administration of ex vivo
expanded MSCs may exert immune-suppressive properties
in vivo, for instance by inducing macrophage polarization. How-
ever, it is still unclear to what extent primary MSCs in the host
play a similar regulatory role. As part of the BM niche, MSCs sup-
port hematopoiesis and restore the differentiated compartment
of osteoblasts and adipocytes during tissue growth and turnover
(Sacchetti et al., 2007). Park et al. (2012) showed that a subset of
Nestin+ MSCs present in vivo are able to replace short-lived
mature osteoblasts to maintain homeostasis and respond to
bone injury.
MSCs may also be involved in tumor progression in a wide
range of cancers. Through the release of soluble factors, tumor
cellsmay recruit myeloid cells from the BM to the tumormicroen-
vironment, where they subsequently promote tumor progression
by conversion into potent immune suppressive cells, including
M2-like Tumor AssociatedMacrophages (TAMs). TAMs promote
tumor growth by producing proangiogenic vascular endothelial
growth factor (VGEF) and immune-suppressive factors (PGE2,
TGF-b) and by releasing chemo-attracting factors (CCL22) that
recruit Tregs (Gabrilovich et al., 2013). Recent evidence indicates
that BM-derived MSCs can also be targeted to the tumor micro-
environment by factors such as stromal cell-derived factor 1
(SDF-1), platelet-derived growth factor a (PDGF-a), and VEGF
(Gabrilovich et al., 2013; Ke et al., 2013; Ren et al., 2012). In the
tumor microenvironment MSCs may be conditioned into tumor-
resident MSCs that acquire functions that are distinct from those
of normal tissue MSCs. One of the mechanisms through which
tumor-resident MSCs promote tumor growth involves the pro-
duction of CCL2, the major chemokine for monocyte trafficking,
which results in the recruitment of immune-suppressive macro-
phages. The chemokine profile and the tumor-promoting proper-
ties of tumor-resident MSCs can be mimicked by stimulating
normalBM-derivedMSCswith TNF-a, suggesting that inflamma-
tion drives tumorigenesis by establishing a link between MSCs
and monocytes and macrophages (Ren et al., 2012; Guilloton
et al., 2012). While their tumor-promoting properties have been
firmly established, other reports suggest that preactivation of
humanMSCs with TNF-amay result in tumor-suppressing activ-
ity mediated by upregulation of TRAIL onMSCs and by induction
of TRAIL-dependent apoptosis of tumor cells (Lee et al., 2012).
The apparent discrepancy between these reports may be ex-
plained by the use of adoptively transferred cells by Lee et al.that donot necessarily represent thephysiological reality (Manto-
vani, 2012). In addition, Lee et al. have used a xeno transplant
model (NOD-SCID), in which adaptive immune (suppressive)
and tumor-promoting responses are lacking. Although mecha-
nisms through which MSCs may promote or suppress tumor
progression are not fully clarified, the possible tumor-promoting
activity of MSCs should be carefully considered in choosing
MSCs for application in cancer patients.
It has been suggested that MSCs play a role in maintaining
fetal maternal tolerance in the placenta and that they express
molecules known to be involved in this process. Both UCB-
and BM-derived MSCs express HLA-G, either in its soluble
form or as a surface antigen (Selmani et al., 2008). It is conceiv-
able that HLA-G expression at the feto-maternal interface is one
of the factors protecting the fetus from maternal immune attack
(Carosella et al., 2008). The expression of HLA-G byMSCs could
contribute to their ability to blunt excessive immune responses
in a specific environment and to control inflammation and main-
tain homeostasis. IDO represents another molecule involved in
the maintenance of fetal maternal tolerance and may also be
produced by MSCs.
Different Biological and Functional Properties of MSCs:
Mouse and Man
While animal models may play a crucial role in dissecting effi-
cacy, it is important to note that murine MSCs are intrinsically
different from human cells (Table 1). Ex vivo expansion with
murine cells is slower than with human cells, and murine MSCs
require weeks before entering a linear growth rate (Phinney
et al., 1999). At this stage, murine MSCs undergo transformation
and immortalization in culture. Several reports have indicated
that transformed murine MSCs have an increased proliferation
rate, display an altered morphology, carry cytogenetic abnor-
malities, and form tumors following injection into syngeneic
mice. Murine BM-derived MSCs in long-term culture gradually
exhibit increased telomerase activity and proceed to amalignant
state, resulting in sarcoma formation in vivo (Miura et al., 2006;
Tolar et al., 2007). This susceptibility to malignant transformation
may be attributed to the high degree of chromosomal instability
in genetically unstable inbred mice, characterized by the devel-
opment of both structural and numerical aberrations even at
early culture passages. Therefore, culture-expanded murine
MSCs should be regarded as transformed cells, even in the
absence of a malignant phenotype. In contrast with these find-
ings, (malignant) transformation of human MSCs has not been
directly demonstrated and attempts to induce a malignant
phenotype by long-term ex vivo expansion have been unsuc-
cessful (Bernardo et al., 2007). In a recent report, its likelihood
has been estimated to be <109 (Prockop et al., 2010) (Table 1).
Many effector molecules that are thought to be involved in the
induction of MSC-mediated immunosuppression are divergent
between mice and humans, although some similarities can be
found. Release of IFN-g by target cells induces the release of
IDO by human MSCs, which is responsible for the inhibition of
T cell proliferation (Krampera, 2011). In mice, IFN-g and TNF-a
stimulates chemokine production by MSCs, resulting in T cell
attraction and increased iNOS, which subsequently produces
NO for inhibition of T cell proliferation (Ren et al., 2008). Not all
immunoinhibitory molecules are divergent between mice andCell Stem Cell 13, October 3, 2013 ª2013 Elsevier Inc. 397
Table 1. Similarities and Differences between Human and Murine MSCs
Human MSCs Murine MSCs
Frequency in BM-MNCs 1:100,000; 1:24,000 1:100,0000; (?)
Growth pattern linear growth lag phase followed by linear growth (Phinney
et al., 1999)
Presence of chromosomal abnormalities rarea (Tarte et al., 2010; Ben-David et al., 2011) invariable (Miura et al., 2006; Tolar et al., 2007)
Transformation and immortalization not reported (Bernardo et al., 2007; Prockop
et al., 2010)
frequent (Miura et al., 2006; Tolar et al., 2007)
Expression of MHC class I/II molecules 100%/<10%b; up to 80%–100%c 100%/<10%b; up to 80%–100%c
Expression of costimulatory molecules ICAM-1; VCAM-1 ICAM-1; VCAM-1
Expression of chemokines, cytokines SDF-1; IL-6; TGF-b; PGE2; LIF; HLA-G; galectins SDF-1; IL-6; TGF-b; PGE2; galectins
Expression of chemokine/cytokine
receptors
IL-1; TNF-a; TLRs; IFN-g; TGF-b IL-1; TNF-a; TLRs; IFN-g; TGF-b
Common effector molecules for immune
regulation
IL-6; PGE2; galectins; IL-10; IL-12 (Najar et al.,
2010; Ghannam et al., 2010)
IL-6; PGE2; galectins; IL-10; IL-12 (Ne´meth et al.,
2009)
Differences in effector molecules for
immune regulation
IDO, HLA-G (Krampera, 2011) NO (Ren et al., 2008)
Key molecules for induction of immune
regulation
IFN-g (induction of IDO) (Krampera, 2011) IFN-g and TNF-a (induction of iNOS/NO) (Ren
et al., 2008)
Cross-species reactivity + murine TNF-a;  murine IFN-g; + murine
NO/IDO
+ human TNF-a;  human IFN-g; + human
IDO/NO
BM-MNCs, bone marrow-mononuclear cells; MHC, major histocompatibility complex; ICAM-1, Intercellular Adhesion Molecule 1; VCAM-1, vascular
cell adhesion molecule 1; SDF-1, stromal cell-derived factor 1; IL-6, interleukin-6; TGF-b, transforming growth factor-b; PGE2, prostaglandin E2;
LIF, leukemia inhibitory factor; HLA-G, human leukocyte antigen_G; TNF-a, tunor necrosis factor- a; TLRs, Toll-like receptors; IFN-g, interferon-g;
IDO, indolamine 2,3 dioxygenase; iNOS, inducible NO synthase; NO, nitric oxide.
aThe presence of chromosomal abnormalities in humanMSCs has been rarely reported. Tarte et al. (2010) reported the presence of aneuploidy in MSC
preparations for clinical use that were found to be related to senescence of the cells and not to transformation. Prockop et al. (2010) estimated the
likelihood of malignant transformation in MSCs to be <109. Ben-David et al. (2011) reported that 4% of theMSC samples that they analyzed harbored
recurrent chromosomal aberrations [3], but the biological significance of these observations was not addressed.
bUnstimulated MSCs.
cAfter MSC activation with cytokines (IFN-g) in the case of human MSCs and dependent on high cell density in the case of murine MSCs.
Cell Stem Cell
Reviewhumans, and PGE2 represents a molecule with a conserved role
in MSC-mediated immunoregulation in both humans and mice.
While human PGE2 and other factors produced by human
MSCs have been shown to participate in the inhibition of T cell
proliferative responses in vitro (Najar et al., 2010), PGE2, in
conjunction with NO, has been reported to induce an inhibitory
IL-10-secreting macrophage phenotype in LPS-containing
cocultures in mice (Ne´meth et al., 2009). Moreover, PGE2 and
IL-6 produced by human MSCs are, at least in part, responsible
for the shift of M0 macrophages into IL-10-producing cells
in vitro (Melief et al., 2013b; Ghannam et al., 2010).
The dissimilarities between MSCs isolated from murine and
human species require a careful evaluation when choosing ani-
mal models to test MSCs in preclinical studies. The contribution
of murine models employing murine/human cells to the develop-
ment of MSC therapy in humans may be limited by the species
differences, as shown for the prevention and treatment of
GvHD. In this context, several animal studies have addressed
the suppressive effect of MSCs, with conflicting results. In one
study, human AT-derived MSCs have been infused systemically
in mice early after transplantation of haploidentical hematopoi-
etic stem cells (HSCs) and were able to rescue the animals
from lethal GvHD (Yan˜ez et al., 2006). Sudres et al. (2006) have
reported that a single dose of murine C57BL/6 BM-derived
MSCs at time of allogeneic BM transplantation did not affect398 Cell Stem Cell 13, October 3, 2013 ª2013 Elsevier Inc.the incidence and severity of GvHD in BALB/c mice, whereas
human UCB-derived MSCs administered at weekly intervals
were able to prevent GvHD development after allogeneic trans-
plantation of human PBMCs in NOD/SCID mice (Tisato et al.,
2007). The same cells were not effective when administered pro-
phylactically immediately after PBMC infusion, nor when they
were infused late in the course of GvHD development. Polchert
et al. (2008) tested the ability of MSCs to prevent GvHD by
administering a single dose of BALB/c BM MSCs into C57BL/6
mice at different time points. A significant increase in survival
of the recipient mice was only observed if MSCs were injected
at day +2 or +20 after the allograft. At these time points the levels
of IFN-g were found to be high in the animals, supporting the
notion that MSCs need to be activated by inflammatory cyto-
kines to deliver their immunosuppressive effect.
The mixed results of MSC treatment on GvHD prevention and
the little effect of MSC infusion on established GvHD reported in
these studies remain unexplained. These discrepancies may be
related to differences between humans and mice in the patho-
genesis of GvHD. In addition, they may be caused by differences
in the biological and functional properties of MSCs or by
subtle differences in the inflammatory status of the host, result-
ing in a proinflammatory or anti-inflammatory MSC secretome.
Finally, they could also be affected by differences in the experi-
mental models employed. Most data have been derived from
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transplantation. Indeed, reports in murine models contrast with
observations in clinical trials, where MSC treatment has been
effective in suppressing established GvHD (Le Blanc et al.,
2008) but has little effect on GvHD (Lazarus et al., 2005). These
differences may relate to the use of different immune effector
molecules between mice and human MSCs (i.e., IDO versus
NO) but may also result from lack of cross-species reactivity of
cytokines. IFN-g is species specific and, therefore, human
MSCs cannot be activated in vivo by mouse IFN-g, but can still
be stimulated by TNF-a since it is not species specific. In spite
of the crucial differences in the use of effector molecules and
the lack of cross-species reactivity of key cytokines such as
IFN-g, human MSCs have shown therapeutic effects in mouse
models of GvHD (Tisato et al., 2007). However, with the excep-
tion of TSG-6 (Lee et al., 2009), the mechanisms of efficacy in
these models remain as yet unclear.
Although MSCs have been applied in a variety of disease
models, including experimental autoimmune encephalomyelitis
(EAE), colitis, retinitis, and myocardial infarction, results are
sometimes difficult to reproduce. Strain-specific induced dis-
ease models may suffer from experimental fine-tuning in order
to arrive at an anticipated outcome. Therefore, there remains a
need for robust animal models to test the in vivo modulatory
properties of MSCs, and data derived from one model in a single
strain may not be sufficient.
Anti-Inflammatory Effects of MSCs in the Clinic:
Treatment of GvHD as a Case Study
Stromal therapy in patients with steroid-refractory acute GvHD
(aGvHD) occurring after allogeneic HSCT and/or donor lympho-
cyte infusion is one of themost extensively investigated potential
clinical applications of MSCs. Following the first report on a pe-
diatric patient experiencing grade IV treatment refractory aGvHD
who was rescued by the infusion of BM-derived MSCs (Le Blanc
et al., 2004), a multitude of pilot studies have been performed. A
phase II, multicenter clinical trial showed a clinical response in
the majority of patients (55 adults and children) with steroid-
resistant aGvHD treated with intravenous infusion(s) of alloge-
neic MSCs. This response translated into a significant difference
in survival between complete responders and partial/nonres-
ponding patients (Le Blanc et al., 2008). These results have
been extended in a cohort of 37 pediatric patients treated with
multiple infusions of MSCs (Ball et al., 2013). Similar results
have been reported in a smaller cohort of pediatric patients
treated with platelet-lysate (PL)-expanded MSCs (Lucchini
et al., 2010). Clearly, these findings need to be confirmed in pro-
spective randomized studies.
The identification of biomarkers that enable evaluation and
quantification of MSC efficacy is of paramount importance for
the development of MSC therapy. Unfortunately, clinical studies
regarding efficacy of MSC treatment have only rarely been used
to identify biomarkers predicting response to MSCs. One
approach could be that of analyzing clinical samples from
GvHD patients treated with MSC infusion(s) to understand the
events underlying patient response in vivo. Dander et al. (2012)
analyzed plasma levels of two biomarkers for aGvHD, i.e., inter-
leukin 2 receptor alpha (IL-2Ra) and tumor necrosis factor recep-
tor (TNFR) I, in a group of patients with aGvHD before and afterMSC treatment. While the levels of the two factors were elevated
before MSC infusion, they persistently decreased in responder
patients, suggesting that these phenomena were related. Inter-
estingly, the same authors observed that one of the patients re-
sponding toMSC treatment showed a decrease in the biomarker
concentrations. Thereafter the patient developed chronic GVHD
(cGvHD) that did not respond to an additional infusion of MSCs,
and the patient’s IL-2Ra and TNFRI levels remained stable or
even increased after the infusion. This observation is in line
with several studies indicating that MSCs need to be activated
by an inflammatory environment to deliver their therapeutic
effect (Krampera, 2011). This environment may be more fre-
quently present during established aGvHD than in cGvHD.
The available evidence suggests that responses to MSC treat-
ment may be independent of the MSC donor or dose of the
immune-suppressive treatment employed. This heterogeneity
in response might be related to the presence or absence of the
appropriate environment in the patient capable of activating
MSCs. Strategies to understand the ongoing patient inflamma-
tory status at the time of MSC infusion could, therefore, allow
the development of relevant biomarkers. It is conceivable that
heterogeneity in responses could be mainly related to host
factors, including an appropriate proinflammatory microenviron-
ment, rather than a result of product-related factors. The conse-
quence of this possibility is that product-related potency assays
may be of relatively little value.
Conclusions and Future Directions
We have reviewed here the regulatory properties of MSCs in
immune-mediated or inflammatory conditions, emphasizing the
central role of the innate immune system in the modulatory
effects of MSCs. In particular, we have highlighted the prominent
role of monocytes/macrophages in orchestrating both proin-
flammatory and anti-inflammatory responses (see Figure 2).
While this model is supported by in vitro and animal studies
(Dazzi et al., 2012; Le Blanc and Mougiakakos, 2012), it should
be noted that it remains to be demonstrated to what extent
these pathways are operational in vivo. There are many
outstanding questions about the physiological role of MSC-
based immune modulation that will need to be addressed to
support further development of their clinical application. While
prospective randomized clinical trials aiming at demonstrating
efficacy and safety are warranted, an adequate understanding
of the underlying mechanisms is required to realize their thera-
peutic potential. An important consequence of the polarization
concept is that immunomodulatory effects of MSCs will be
largely determined by local inflammatory conditions in the
host. Timing and route of delivery of MSC treatment may, there-
fore, be critical in determining the treatment responses in
patients. Biomarkers predictive for response are not yet avail-
able, but the notion that early treatment with MSCs for
steroid-resistant aGvHD may be more effective than treatment
initiated later in the course of GvHD is in accordance with this
hypothesis (Ball et al., 2013).
There is a clear need to develop animal models that appro-
priately address the complex interplay between the ‘‘MSC
product’’ and the host microenvironment where these cells
execute their regulatory function. Insight into the in vitro modu-
latory networks that result in the generation of anti-inflammatoryCell Stem Cell 13, October 3, 2013 ª2013 Elsevier Inc. 399
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models to address these issues.
Regarding their therapeutic effect, MSCs may serve as drug
delivery vehicles at local sites of inflammation. Novel molecular
tools aimed at defining theMSC secretome, proteome, and tran-
scriptome are being employed to more precisely define the sol-
uble factors that mediate MSC function (Ranganath et al., 2012).
These tools include MSC-derived microvesicles or exosomes
that can mediate intercellular communication between MSCs
and other cells (Biancone et al., 2012). As far as the endocrine
effects of MSCs are concerned, it is conceivable that identifica-
tion of relevant effector molecules could lead to novel treatment
modalities that might eventually replace cellular therapy with
MSCs. However, the effector functions of MSCs may also
depend on paracrine mechanisms that are mediated by the
concerted interaction between different molecules that are deliv-
ered locally through the directed migration of cells to a site of
injury. This complexity must be considered when designing
novel therapeutic strategies with MSCs. The latter strategy
would open the possibility to direct migration and engineer
MSCs in order to deliver effector molecules at particular (tis-
sue-specific) sites (Sarkar et al., 2010; Levy et al., 2013).
MSC therapy has entered the clinic in a variety of applications
related to tissue repair and alloimmune or autoimmune disorders
(Le Blanc et al., 2008; Duijvestein et al., 2010). According to the
clinical trial registry at the National Institute of Health, over 350
clinical trials are currently being conducted with these cells
(http://clinicaltrials.gov). Other potentially promising indications
include the use of MSCs in solid organ transplantation with the
aim of reducing the use of immune-suppressive drugs or treating
chronic rejection (Casiraghi et al., 2013). The potential use of
MSCs in tolerance induction in organ transplantation relates to
their ability to skew the balance between effector T cells and reg-
ulatory T cells. In autoimmune disorders, the use of MSC therapy
in luminal Crohn’s disease or Crohn’s fistulas is currently under
study (Ciccocioppo et al., 2011).
MSC therapy represents an emerging modality of alternative
treatment with the capacity to provide site-specific immunoreg-
ulation to control pathogenic T cell responses that drive autoim-
munity and allograft rejection. Prospective randomized studies
are needed to determine the true scope of the therapeutic
potential and provide clear evidence of reproducible efficacy.
Nevertheless, this promising property of MSCs, independent
of their HSC-supporting capacity, warrants extensive further
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